Neoantigen Cancer Vaccine Market, By Vaccine Type (Personalized Neoantigen Vaccines and Off-the-Shelf (Shared Neoantigen) Vaccines), By Technology Platform, By Cancer Type, By End User, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4667
|
Published Date
January 2026
|
Pages
356
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Neoantigen Cancer Vaccine Market size was valued at US$ 370.87 Million in 2024, expanding at a CAGR of 14.9% from 2025 to 2032.
The Neoantigen Cancer Vaccine market focuses on therapeutic vaccines targeting neoantigens, which are mutated proteins expressed on tumor cells but absent on healthy cells. This positions neoantigen vaccines within the broader precision oncology paradigm, where treatments are tailored to the unique biology of individual tumors. Market progress is closely tied to advancements in next-generation sequencing, improved computational prediction of immunogenic neoantigens, and faster manufacturing platforms, including mRNA and synthetic peptides. Interest in neoantigen vaccines has increased as early and mid-stage studies indicate they may work synergistically with checkpoint inhibitors and could be particularly effective post-surgery, when tumor burden is low, to reduce the risk of relapse.
Commercial adoption is heavily dependent on operational execution, especially for personalized vaccines that require seamless coordination from tumor biopsy and sequencing to vaccine design, production, and clinical delivery within a practical timeline. Key considerations for decision-makers include reducing turnaround time, scaling manufacturing without compromising quality, and maintaining robust chain-of-custody and chain-of-identity systems for individualized products. The competitive landscape features biotech companies developing neoantigen discovery and vaccine platforms, alongside large pharmaceutical firms that can integrate vaccines with existing immunotherapy portfolios and conduct global clinical trials. Over the coming years, market growth will likely hinge on late-stage clinical outcomes, regulatory approvals for personalized therapies, and evidence demonstrating clinically meaningful benefits, such as extended recurrence-free survival in defined patient populations.
Neoantigen Cancer Vaccine Market- Market Dynamics
Rising Cancer Incidence and Expanded Tumor Sequencing Drive Neoantigen Vaccine Adoption
The Neoantigen Cancer Vaccine market is being driven by a combination of a rising global cancer burden and the expanding use of tumor genomic testing, as the design of neoantigen vaccines relies on identifying tumor-specific mutations through sequencing. The clinical need is both large and persistent. According to the International Agency for Research on Cancer (IARC, WHO GLOBOCAN 2022), there were approximately 20.0 million new cancer cases and 9.7 million cancer-related deaths worldwide in 2022, placing ongoing pressure on healthcare systems to adopt more effective immunotherapies, particularly for patients at high risk of recurrence.
The scale of the U.S. market reflects this trend. The National Cancer Institute (NCI) projects around 2.0 million new cancer cases and more than 600,000 deaths in 2024, highlighting strong demand for therapies that can improve recurrence-free and overall survival. Concurrently, precision oncology infrastructure is advancing, making personalized treatment approaches increasingly practical. The U.S. Food and Drug Administration (FDA) reports that multiple next-generation sequencing (NGS) oncology tests have been cleared or approved, and the oncology NGS landscape continued to expand between 2020 and 2024. This expansion enables broader routine mutation profiling, which is critical for identifying neoantigens for vaccine development. Together, these factors—large patient volumes driving demand and enhanced sequencing capacity enabling personalized therapies—underscore the growing interest in neoantigen vaccines and combination strategies in clinical development.
Neoantigen Cancer Vaccine Market- Segmentation Analysis:
Personalized neoantigen vaccines are closely linked to the expansion of precision oncology infrastructure, as individualized vaccine design begins with tumor sequencing and mutation identification. The large and growing cancer population sustains a significant opportunity for these therapies. According to the International Agency for Research on Cancer (IARC, WHO GLOBOCAN 2022), approximately 20.0 million new cancer cases were reported worldwide in 2022, supporting ongoing demand for immunotherapies that go beyond standard treatments. The U.S. patient population is similarly substantial. The National Cancer Institute (NCI) projects around 2.0 million new cancer cases in 2024, reinforcing the need for approaches that can be tailored to high-risk patients and potentially reduce relapse.
Clinical testing capabilities are improving as sequencing becomes more routine. The U.S. Food and Drug Administration (FDA) reports that the number and scope of cleared or approved oncology next-generation sequencing (NGS) tests expanded steadily between 2020 and 2024. This broader access to tumor mutation profiling facilitates neoantigen selection workflows and helps shorten the timeline from vaccine design to treatment.
mRNA-based neoantigen platforms are benefiting from the maturation of mRNA technology, which moved from an emerging approach to a validated manufacturing and regulatory reality after 2020. Large-scale production and distribution capabilities have been demonstrated at a scale few other platforms can match. According to the U.S. Centers for Disease Control and Prevention (CDC), hundreds of millions of COVID19 vaccine doses were administered in the United States, with reporting continuing through 2024, proving that mRNA products can be manufactured and delivered at scale with established quality systems. Regulatory familiarity also increased during this period. The FDA’s multiple authorizations, approvals, and formulation updates for COVID19 vaccines between 2020 and 2023 clarified expectations around manufacturing controls, product modifications, and lifecycle management—insights that are directly applicable to the development of therapeutic mRNA cancer vaccines.
Neoantigen Cancer Vaccine Market- Geographical Insights
Neoantigen cancer vaccine development is primarily concentrated in regions with established oncology research networks, routine tumor sequencing capabilities, and the infrastructure to support complex biologic manufacturing and logistics. North America and Europe remain key markets due to higher adoption of precision medicine and the presence of major cancer centers capable of supporting advanced clinical trials. The clinical need is substantial and continues to grow. According to the International Agency for Research on Cancer (IARC, WHO GLOBOCAN 2022), there were approximately 20.0 million new cancer cases and 9.7 million cancer-related deaths worldwide in 2022, underscoring the pressure on healthcare systems to identify more effective therapies that improve long-term outcomes.
Enabling tools for neoantigen development are also expanding. The U.S. Food and Drug Administration (FDA) reports that multiple oncology next-generation sequencing (NGS) tests have been cleared or approved, and the oncology NGS landscape continued to grow through 2020–2024. This expansion supports broader tumor mutation profiling, which is critical for neoantigen selection. Confidence in manufacturing RNA-based vaccines has likewise increased following the COVID-19 pandemic. According to the U.S. Centers for Disease Control and Prevention (CDC), hundreds of millions of COVID19 vaccine doses were administered in the United States through 2024, demonstrating that large-scale RNA product manufacturing and distribution can be reliably executed at a national level.
United States Neoantigen Cancer Vaccine Market- Country Insights
The United States stands out as the most favorable single-country environment for neoantigen cancer vaccines, thanks to its large oncology patient population, high clinical trial activity, and advanced precision oncology infrastructure. The demand for novel therapies is significant: according to the National Cancer Institute (NCI), the U.S. is projected to see approximately 2.0 million new cancer cases and over 600,000 cancer-related deaths in 2024, driving continued investment in treatments designed to prevent recurrence and extend survival.
Personalized vaccine development relies on access to tumor sequencing, and the availability of regulatory-cleared testing has been steadily increasing. The U.S. Food and Drug Administration (FDA) reports that the number of cleared or approved oncology next-generation sequencing (NGS) tests continued to grow from 2020 to 2024, facilitating broader integration of mutation profiling into clinical workflows.
The U.S. also has practical experience in large-scale mRNA production and quality management. According to the U.S. Centers for Disease Control and Prevention (CDC), cumulative COVID19 vaccine administration reached hundreds of millions of doses through 2024, demonstrating the country’s capacity to manufacture and distribute mRNA-based therapeutics at scale—a capability directly relevant to neoantigen vaccine supply chains.
Neoantigen Cancer Vaccine Market- Competitive Landscape:
The competitive landscape for neoantigen cancer vaccines generally includes mRNA platform leaders, immuno-oncology companies developing checkpoint inhibitors for combination therapies, and specialists focused on neoantigen discovery and tumor profiling. BioNTech SE and Moderna, Inc. are recognized for their strong mRNA platform capabilities and rapid design-to-manufacture cycles, which are critical for individualized vaccines with tight turnaround timelines. Merck & Co., Inc., Bristol-Myers Squibb Company, and Roche Holding AG (including Genentech, Inc.) are notable for their clinical development scale and potential to combine therapies with PD-1/PD-L1 inhibitors. Gritstone Bio, Inc. and Immatics N.V. are often associated with expertise in neoantigen selection, T-cell epitope mapping, and computational prioritization methods, while Personalis, Inc. and NEC Corporation are frequently referenced for tumor profiling and data-driven workflows that support neoantigen identification. Real-world readiness in this market is closely tied to high cancer incidence and expanding sequencing capabilities (IARC, WHO), as well as large-scale RNA manufacturing experience demonstrated during the COVID-19 pandemic (CDC), which together enable broader adoption and practical deployment of personalized neoantigen vaccine programs.
Recent Developments:
- November 2025: The Japanese Foundation for Cancer Research (JFCR), NEC Corporation, and Taiho Pharmaceutical Co., Ltd. signed a three-party joint research agreement under a Japan Agency for Medical Research and Development (AMED) program. The collaboration aims to develop new cancer vaccines using whole-genome information. The project focuses on shared neoantigen vaccines by combining JFCR’s whole-genome datasets linked to clinical data, NEC’s predictive AI for antigen identification (including cryptic antigens from the “dark genome”), and Taiho’s immunological evaluation models to select vaccine candidates suitable for clinical trials and broad patient applicability.
- August 2025: Neomatrix Biotech outlined a platform for identifying tumor-specific neoantigens and producing fully synthetic, personalized DNA vaccines with a target turnaround of approximately six weeks from tumor biopsy. The approach is designed for combination with immune checkpoint inhibitors, using next-generation sequencing, proprietary neoantigen selection filters, and delivery via electroporation. Plans include a lung cancer clinical trial in the second half of 2025, with ongoing efforts to monitor recurrence and update vaccine targets using circulating tumor DNA.
- March 2025: The Icahn School of Medicine at Mount Sinai published early clinical results for PGV001, a personalized multi-peptide neoantigen vaccine evaluated in a Phase 1 trial with 13 patients across multiple cancer types. Findings, reported in Cancer Discovery (AACR), indicated that the vaccine was feasible to manufacture and did not produce serious adverse events. At five-year follow-up, six patients were alive, with three remaining tumor-free. The dataset supports planned trials in glioblastoma, urothelial cancer (in combination with checkpoint inhibitors), and prostate cancer.
- June 2022: CureVac N.V. announced the acquisition of Frame Cancer Therapeutics, a genomics and bioinformatics company specializing in unique and shared neoantigen identification. The €32 million deal, paid in CureVac shares with milestone-based components, added Frame’s FramePro antigen discovery platform to strengthen neoantigen identification and validation for mRNA cancer vaccine programs, expanding CureVac’s discovery capabilities at Amsterdam Science Park.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL NEOANTIGEN CANCER VACCINE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Amgen Inc.
- AstraZeneca PLC
- BeiGene, Ltd.
- BioNTech SE
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- Genentech, Inc.
- Gritstone bio, Inc.
- GSK plc
- Immatics N.V.
- Johnson & Johnson
- Merck & Co., Inc.
- Moderna, Inc.
- NEC Corporation
- Novartis AG
- Personalis, Inc.
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- Roche Holding AG
- Sanofi
- Others
GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY VACCINE TYPE- MARKET ANALYSIS, 2019 - 2032
- Personalized Neoantigen Vaccines
- Off-the-Shelf (Shared Neoantigen) Vaccines
GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY TECHNOLOGY PLATFORM- MARKET ANALYSIS, 2019 - 2032
- mRNA-Based
- Peptide/Protein-Based
- DNA-Based
- Dendritic Cell-Based
- Other Platforms
GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY CANCER TYPE- MARKET ANALYSIS, 2019 - 2032
- Melanoma
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Other Cancers
GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
- Hospitals & Cancer Centers
- Specialty Clinics
- Research Institutes & Academic Centers
- Pharmaceutical & Biotechnology Companies
- Contract Research/Manufacturing Organizations (CROs/CMOs)
- Others
GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Neoantigen Cancer Vaccine Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Neoantigen Cancer Vaccine Market Snippet by Vaccine Type
2.1.2. Neoantigen Cancer Vaccine Market Snippet by Technology Platform
2.1.3. Neoantigen Cancer Vaccine Market Snippet by Cancer Type
2.1.4. Neoantigen Cancer Vaccine Market Snippet by End User
2.1.5. Neoantigen Cancer Vaccine Market Snippet by Country
2.1.6. Neoantigen Cancer Vaccine Market Snippet by Region
2.2. Competitive Insights
3. Neoantigen Cancer Vaccine Key Market Trends
3.1. Neoantigen Cancer Vaccine Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Neoantigen Cancer Vaccine Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Neoantigen Cancer Vaccine Market Opportunities
3.4. Neoantigen Cancer Vaccine Market Future Trends
4. Neoantigen Cancer Vaccine Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Neoantigen Cancer Vaccine Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Neoantigen Cancer Vaccine Market Landscape
6.1. Neoantigen Cancer Vaccine Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Neoantigen Cancer Vaccine Market – By Vaccine Type
7.1. Overview
7.1.1. Segment Share Analysis, By Vaccine Type, 2024 & 2032 (%)
7.1.2. Personalized Neoantigen Vaccines
7.1.3. Off-the-Shelf (Shared Neoantigen) Vaccines
8. Neoantigen Cancer Vaccine Market – By Technology Platform
8.1. Overview
8.1.1. Segment Share Analysis, By Technology Platform, 2024 & 2032 (%)
8.1.2. mRNA-Based
8.1.3. Peptide/Protein-Based
8.1.4. DNA-Based
8.1.5. Dendritic Cell-Based
8.1.6. Other Platforms
9. Neoantigen Cancer Vaccine Market – By Cancer Type
9.1. Overview
9.1.1. Segment Share Analysis, By Cancer Type, 2024 & 2032 (%)
9.1.2. Melanoma
9.1.3. Lung Cancer
9.1.4. Colorectal Cancer
9.1.5. Breast Cancer
9.1.6. Other Cancers
10. Neoantigen Cancer Vaccine Market – By End User
10.1. Overview
10.1.1. Segment Share Analysis, By Technology Platform, 2024 & 2032 (%)
10.1.2. Hospitals & Cancer Centers
10.1.3. Specialty Clinics
10.1.4. Research Institutes & Academic Centers
10.1.5. Pharmaceutical & Biotechnology Companies
10.1.6. Contract Research/Manufacturing Organizations (CROs/CMOs)
10.1.7. Others
11. Neoantigen Cancer Vaccine Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
11.2.1. Overview
11.2.2. Neoantigen Cancer Vaccine Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.2.4. North America Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.2.5. North America Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.2.6. North America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Neoantigen Cancer Vaccine Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.3.10.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Neoantigen Cancer Vaccine Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.4.7. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.4.8.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.4.9.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Neoantigen Cancer Vaccine Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Neoantigen Cancer Vaccine Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.6.7. MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Technology Platform, 2019 - 2032 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12. Key Vendor Analysis- Neoantigen Cancer Vaccine Industry
12.1. Competitive Benchmarking
12.1.1. Competitive Dashboard
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. Amgen Inc.
12.2.2. AstraZeneca PLC
12.2.3. BeiGene, Ltd.
12.2.4. BioNTech SE
12.2.5. Bristol-Myers Squibb Company
12.2.6. F. Hoffmann-La Roche Ltd
12.2.7. Genentech, Inc.
12.2.8. Gritstone bio, Inc.
12.2.9. GSK plc
12.2.10. Immatics N.V.
12.2.11. Johnson & Johnson
12.2.12. Merck & Co., Inc.
12.2.13. Moderna, Inc.
12.2.14. NEC Corporation
12.2.15. Novartis AG
12.2.16. Personalis, Inc.
12.2.17. Pfizer Inc.
12.2.18. Regeneron Pharmaceuticals, Inc.
12.2.19. Roche Holding AG
12.2.20. Sanofi
12.2.21. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL NEOANTIGEN CANCER VACCINE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Amgen Inc.
- AstraZeneca PLC
- BeiGene, Ltd.
- BioNTech SE
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- Genentech, Inc.
- Gritstone bio, Inc.
- GSK plc
- Immatics N.V.
- Johnson & Johnson
- Merck & Co., Inc.
- Moderna, Inc.
- NEC Corporation
- Novartis AG
- Personalis, Inc.
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- Roche Holding AG
- Sanofi
- Others
GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY VACCINE TYPE- MARKET ANALYSIS, 2019 - 2032
- Personalized Neoantigen Vaccines
- Off-the-Shelf (Shared Neoantigen) Vaccines
GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY TECHNOLOGY PLATFORM- MARKET ANALYSIS, 2019 - 2032
- mRNA-Based
- Peptide/Protein-Based
- DNA-Based
- Dendritic Cell-Based
- Other Platforms
GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY CANCER TYPE- MARKET ANALYSIS, 2019 - 2032
- Melanoma
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Other Cancers
GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
- Hospitals & Cancer Centers
- Specialty Clinics
- Research Institutes & Academic Centers
- Pharmaceutical & Biotechnology Companies
- Contract Research/Manufacturing Organizations (CROs/CMOs)
- Others
GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
